SCHEMBL26077933

SCHEMBL26077933

CC(C)c1ccc(F)c(C(=O)Nc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 2/20 0.56
LCK P06239 2/20 0.55
KDR P35968 1/20 0.55
TEK Q02763 1/20 0.55
PTGS1 P23219 1/20 0.55
RXFP1 Q9HBX9 10/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
SLC2A1 P11166 1/20 0.55
P2RX4 Q99571 1/20 0.55
P2RX7 Q99572 1/20 0.55
TMPRSS4 Q9NRS4 1/20 0.55
MAPT P10636 2/20 0.54
TP53 P04637 1/20 0.52
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
OPRK1 P41145 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075652 0.91 P2RX1 (0.54) P2RX1LCKKDRTEKPTGS1
SCHEMBL17660212 0.84 TLR8 (0.54) P2RX1SMN1; SMN2P2RX4P2RX7TMPRSS4
SCHEMBL26075815 0.82 P2RX1 (0.59) P2RX1LCKKDRTEKPTGS1
SCHEMBL29537581 0.81 MEN1 (0.67) P2RX1LCKKDRTEKPTGS1
SCHEMBL20577892 0.81 P2RX1 (0.60) P2RX1LCKKDRTEKPTGS1
SCHEMBL25231718 0.81 MEN1 (0.67) P2RX1LCKKDRTEKPTGS1
SCHEMBL5496719 0.81 RXFP1 (0.60) P2RX1LCKKDRTEKPTGS1
SCHEMBL22025444 0.79 KMT2A (0.68) KDRSMN1; SMN2MAPTTP53KDM4E
SCHEMBL14445617 0.79 MAPT (0.70) P2RX1PTGS1RXFP1MAPTMEN1
SCHEMBL29448774 0.78 RXFP1 (0.71) P2RX1LCKKDRTEKPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 P2RX1 1108/4885LCK 55/4885KDR 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.